Opendata, web and dolomites

Renaparin SIGNED

Improving kidney transplantation outcome with Renaparin® for patients with End-Stage Renal Disease by attenuating graft ischemia reperfusion injury

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Renaparin project word cloud

Explore the words cloud of the Renaparin project. It provides you a very rough idea of what is the project "Renaparin" about.

ischemia    realize    internationally    substantially    supports    preliminary    supply    vascular    recipient    criteria    endothelium    constitute    turn    donor    pressing    wall    community    surgeons    corline    activate    trial    cell    prior    strategy    tissue    innate    reduces    stored    kidney    replacement    repairs    pharmaceutical    compound    oxygen    basis    establishing    leads    injury    biomedical    nephrologists    prevention    reg    renaparin    drug    iri    performed    chances    of    lining    rejection    natural    commercialisation    kidneys    replaces    outcome    immune    blood    humans    awaiting    technologies    connected    binds    lack    extend    host    clinical    preparation    damaged    safety    shortage    validate    vessels    reperfusion    alarming    strategic    solution    extracted    emphasise    efficacy    safe    flow    organ    survival    data    cornerstone    iia    organs    preservation    lies    coat    accelerated    transplantation    cells    glucose    protects   

Project "Renaparin" data sheet

The following table provides information about the project.

Coordinator
CORLINE BIOMEDICAL AB 

Organization address
address: LEFFLERSGATAN 5
city: UPPSALA
postcode: 754 50
website: www.corline.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.corline.se
 Total cost 2˙362˙681 €
 EC max contribution 2˙362˙681 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CORLINE BIOMEDICAL AB SE (UPPSALA) coordinator 2˙362˙681.00

Map

 Project objective

This project will validate the safety and efficacy of Corline Biomedical’s pharmaceutical compound Renaparin®, a novel cell replacement technology used to coat the lining of the blood vessels of kidneys prior to transplantation. Donor kidneys lack natural blood flow while awaiting transplantation. This can lead to ischemia (a shortage of oxygen and glucose supply to the kidney tissue). When connected to the recipient’s blood flow, this in turn leads to ischemia reperfusion injury (IRI).

Given the alarming shortage of organs available for transplantation in the EU and internationally, the prevention of IRI has become a top priority for the transplantation community. Transplantation surgeons and nephrologists emphasise the pressing need for safe and effective technologies which can improve the outcome of kidney transplantation and extend donor criteria. Renaparin® is used when the kidney has been extracted from the donor and is stored in preservation solution awaiting transplantation. There, it binds to, replaces, repairs and protects damaged kidney cells on the endothelium of the vascular wall. As a result, a kidney is less likely to activate the host’s innate immune system, which increases the chances of organ survival and substantially reduces the likelihood of organ rejection.

The research performed in preparation of further development of Renaparin® strongly supports the drug’s potential to increase the success of kidney transplantation. The activities proposed in this project will bring Renaparin® through a Phase I/IIa clinical trial in humans. The produced clinical safety data and preliminary clinical efficacy data will constitute the basis for further clinical development and commercialisation of the product.

Corline’s strategic focus lies on establishing Renaparin® as a new cell replacement technology in kidney transplantation. This will constitute the cornerstone of Corline’s accelerated growth. The project is the key step to realize this strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RENAPARIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RENAPARIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More